Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Robert T. Brodell MD, FAAD Editor-in-Chief

Jane M. Grant-Kels MD, FAAD Advisory Board

Ashish C. Bhatia MD, FAAD Associate Editor

See All Experts

Published in Dermatology

News · May 05, 2021

AAD VMX 2021: The Future of Janus Kinase Inhibitors in Dermatology Is Bright

While no indications exist yet in dermatology, off-label and experimental use show promise

PracticeUpdate Editorial Team

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

featured

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

J Eur Acad Dermatol Venereol · November 21, 2024
featured

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Int. J. Dermatol · November 21, 2024
featured

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

J Am Acad Dermatol · November 21, 2024
featured

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Arch Dermatol Res · November 20, 2024

updated
featured

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

J Am Acad Dermatol · November 20, 2024
story of the week

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

J Am Acad Dermatol · November 20, 2024
featured

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Dermatol Surg · November 20, 2024
featured

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

J Am Acad Dermatol · November 19, 2024
featured

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Br J Dermatol · November 19, 2024

updated
featured

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

J Am Acad Dermatol · November 19, 2024

updated
featured

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma, Atypical Spitz Tumors, and Non-Spitz Melanocytic Tumors

J. Clin. Oncol · November 14, 2024

AAD VMX 2021: The Future of Janus Kinase Inhibitors in Dermatology Is Bright

Further Reading

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma, Atypical Spitz Tumors, and Non-Spitz Melanocytic Tumors

Recently Updated